1-3 of 3
Mario R. Ehlers
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Preclinical Consortium Approach for Assessing the Efficacy of Combined Anti-CD3 Plus IL-1 Blockade in Reversing New-Onset Autoimmune Diabetes in NOD Mice

Ronald G. Gill, Philippe P. Pagni, Tinalyn Kupfer, Clive H. Wasserfall, Songyan Deng, Amanda Posgai, Yulia Manenkova, Amira Bel Hani, Laura Straub, Philip Bernstein, Mark A. Atkinson, Kevan C. Herold, Matthias von Herrath, Teodora Staeva, Mario R. Ehlers, Gerald T. Nepom
Journal: Diabetes
Diabetes 2016;65(5):1310–1316
https://doi.org/10.2337/db15-0492
Published: 31 December 2015
View article titled, A Preclinical Consortium Approach for Assessing the Efficacy of Combined Anti-CD3 Plus IL-1 Blockade in Reversing New-Onset Autoimmune Diabetes in NOD Mice
Open the PDF for A Preclinical Consortium Approach for Assessing the Efficacy of Combined Anti-CD3 Plus IL-1 Blockade in Reversing New-Onset Autoimmune Diabetes in NOD Mice in another window
Includes: Supplementary data
Journal Articles

Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial: Metabolic and Immunologic Features at Baseline Identify a Subgroup of Responders

Kevan C. Herold, Stephen E. Gitelman, Mario R. Ehlers, Peter A. Gottlieb, Carla J. Greenbaum, William Hagopian, Karen D. Boyle, Lynette Keyes-Elstein, Sudeepta Aggarwal, Deborah Phippard, Peter H. Sayre, James McNamara, Jeffrey A. Bluestone, and the AbATE Study Team
Journal: Diabetes
Diabetes 2013;62(11):3766–3774
https://doi.org/10.2337/db13-0345
Published: 18 October 2013
View article titled, Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial: <subtitle>Metabolic and Immunologic Features at Baseline Identify a Subgroup of Responders</subtitle>
Open the PDF for Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial: <subtitle>Metabolic and Immunologic Features at Baseline Identify a Subgroup of Responders</subtitle> in another window
Includes: Supplementary data
Journal Articles

Rapamycin/IL-2 Combination Therapy in Patients With Type 1 Diabetes Augments Tregs yet Transiently Impairs β-Cell Function

S. Alice Long, Mary Rieck, Srinath Sanda, Jennifer B. Bollyky, Peter L. Samuels, Robin Goland, Andrew Ahmann, Alex Rabinovitch, Sudeepta Aggarwal, Deborah Phippard, Laurence A. Turka, Mario R. Ehlers, Peter J. Bianchine, Karen D. Boyle, Steven A. Adah, Jeffrey A. Bluestone, Jane H. Buckner, Carla J. Greenbaum
Journal: Diabetes
Diabetes 2012;61(9):2340–2348
https://doi.org/10.2337/db12-0049
Published: 17 August 2012
View article titled, Rapamycin/IL-2 Combination Therapy in Patients With Type 1 Diabetes Augments Tregs yet Transiently Impairs β-Cell Function
Open the PDF for Rapamycin/IL-2 Combination Therapy in Patients With Type 1 Diabetes Augments Tregs yet Transiently Impairs β-Cell Function in another window
Includes: Supplementary data